Does TRICARE Cover Lantus (Insulin Glargine)? Coverage, Prior Authorization, and Appeals

What Is Lantus and Why Does Formulary Placement Matter?

Lantus is a brand-name basal insulin containing insulin glargine 100 units/mL, manufactured by Sanofi. It delivers a flat, peakless 24-hour action profile that makes once-daily dosing practical for most adults with type 1 diabetes (T1D) or insulin-requiring type 2 diabetes (T2D) [1]. The FDA originally approved Lantus in April 2000, and the product label has since been updated multiple times to reflect expanded pediatric use and new safety language [2].

Formulary placement determines out-of-pocket cost. When an insurer places a drug on a non-preferred tier, you pay a higher copay or coinsurance percentage than you would for a preferred or generic alternative. TRICARE uses a tiered formulary that mirrors the Defense Health Agency (DHA) uniform formulary policy [3]. Lantus sits on the non-preferred brand tier for most TRICARE plan types, which raises your cost-share substantially compared with preferred biosimilar alternatives like Semglee or Basaglar.

Clinically, insulin glargine remains a first-line basal insulin. The American Diabetes Association 2025 Standards of Care continue to recommend basal insulin as a core component of T1D management and as an intensification option in T2D when oral agents and GLP-1 receptor agonists have not achieved glycemic targets [4]. TRICARE's coverage policy does not question the clinical rationale for basal insulin broadly. The friction arises specifically around which brand of basal insulin you receive.

TRICARE Formulary Status for Lantus

Lantus is classified as a non-preferred brand on the TRICARE uniform formulary. This means it is covered but at a higher cost-share than preferred alternatives.

Under the TRICARE pharmacy benefit, drugs fall into four broad cost categories: generic (Tier 1), preferred brand (Tier 2), non-preferred brand (Tier 3), and non-covered [3]. Lantus occupies Tier 3 for most TRICARE beneficiaries. The cost-share structure differs by where you fill your prescription.

At a military treatment facility (MTF) pharmacy, most covered formulary drugs are available at no cost to the beneficiary, including non-preferred brands when authorized. At a TRICARE retail network pharmacy, Tier 3 drugs carry a higher copay than preferred brands, typically $49 for a 30-day supply for active-duty family members and a higher percentage coinsurance for retirees [3]. Mail-order through Express Scripts (the TRICARE pharmacy contractor) offers a 90-day supply at a reduced rate compared with retail, but the non-preferred Tier 3 cost-share still applies to Lantus.

The preferred basal insulin alternatives on TRICARE currently include:

• Semglee (insulin glargine-yfgn, Mylan/Viatris), FDA-designated interchangeable biosimilar to Lantus [5]
• Basaglar (insulin glargine, Eli Lilly), a follow-on biologic
• Rezvoglar (insulin glargine-aglr, Eli Lilly), another interchangeable biosimilar [6]

Because Semglee is FDA-designated as interchangeable with Lantus, a pharmacist may substitute it without a new prescription in most states [5]. If you receive a Lantus prescription and your pharmacy automatically fills it with Semglee, that substitution is legally and clinically valid. Notify your prescriber so your chart is updated, but no clinical harm results from the switch for most patients.

Prior Authorization Criteria for Lantus on TRICARE

TRICARE rates the prior authorization (PA) difficulty for Lantus as moderate. Approval is feasible but requires documentation.

The standard PA criteria for Lantus on TRICARE center on three questions the reviewer will ask [3]:

1. Does the patient have a confirmed diagnosis of T1D or insulin-requiring T2D?
2. Has the patient tried and failed, or has a clinical reason to avoid, preferred basal insulin alternatives (Semglee, Basaglar, Rezvoglar)?
3. Is the prescribing provider documenting medical necessity for the brand-name product specifically?

For T1D, the "tried and failed" standard is more flexible because any disruption to a stable basal insulin regimen carries meaningful risk of hypoglycemia or ketoacidosis. Endocrinologists writing PA letters for T1D patients should cite current HbA1c, time-in-range data where available, and any documented adverse response or suboptimal control on a biosimilar. The ADA notes that insulin pens and delivery devices differ between biosimilar products, and device familiarity is a legitimate clinical consideration [4].

For T2D, TRICARE reviewers are more likely to require documentation that a preferred biosimilar was dispensed and caused a measurable clinical problem, or that a clinical reason (pen incompatibility, patient refusal of a new training process, provider-documented concern) justifies continued brand use.

PA approval periods for Lantus on TRICARE typically run 12 months, after which re-authorization is required. Your prescriber's office should submit the PA using the TRICARE-specific prior authorization request form through the Express Scripts online portal or by fax to the TRICARE pharmacy benefit manager [3].

Step Therapy Requirements Before Lantus

TRICARE does require step therapy for Lantus in most T2D cases. The step requirement is less strictly enforced in T1D.

Step therapy (sometimes called "fail-first") means the insurer requires you to try a lower-tier drug before it will cover the higher-tier drug. For Lantus on TRICARE, the required step drugs are the preferred basal insulins listed above, primarily Semglee and Basaglar [3]. In some cases, older agents like NPH insulin (available at very low cost) may appear in the step protocol for T2D patients who have not yet started any basal insulin.

The clinical community has raised concerns about step therapy for insulin products. Switching an established T1D patient off a stable Lantus regimen to satisfy a step requirement creates an unnecessary risk window. The Endocrine Society's clinical practice guideline on insulin therapy states that stable glycemic control on a current regimen is itself a clinical reason to avoid mandatory substitution [7]. Use this language in PA letters for patients already well-controlled on Lantus.

Step therapy exemptions under federal law may apply. The Removing Barriers to Colorectal Cancer Screening Act and related step therapy reform provisions for Medicare Advantage do not directly apply to TRICARE, but the DHA has internal guidance stating that step therapy should not be applied when a physician certifies that the required first-step drug is contraindicated, previously caused an adverse reaction, or is clinically inappropriate for the individual patient [3]. A one-page letter from your endocrinologist covering any of those three points is typically enough to waive the step requirement.

How to Appeal a TRICARE Denial of Lantus

A TRICARE denial of Lantus is not the end of the road. Three sequential appeal options exist.

Step 1: Reconsideration request. Within 90 days of the denial notice, submit a written reconsideration request to Express Scripts (the TRICARE pharmacy benefit manager). Include the prescriber's PA letter, any supporting clinical notes, relevant lab values (HbA1c, continuous glucose monitor reports if available), and a statement of medical necessity. Express Scripts must respond within 72 hours for urgent cases and 30 days for standard cases [3].

Step 2: TRICARE formal appeal. If reconsideration is denied, you may file a formal appeal with your regional TRICARE managed care support contractor. As of 2025, TRICARE East is managed by Humana Military and TRICARE West by Health Net Federal Services. Submit your appeal in writing, attach all prior documentation, and request a written decision. The contractor must respond within 60 days [3].

Step 3: Independent review. If the formal appeal is denied, you may request an external independent review. TRICARE beneficiaries also retain the right to escalate to the DHA appeals office. For active-duty members, the Patient Advocate at your MTF can help coordinate this process.

A useful documentation framework for Lantus appeals includes four elements: (1) the clinical diagnosis with ICD-10 code (E10.x for T1D, E11.x for T2D), (2) the specific reason the preferred biosimilar is inadequate or inappropriate, (3) time-stamped records showing the patient's current glycemic control, and (4) a direct citation to the clinical guideline supporting brand-name continuity. Appeals that include all four elements have a substantially higher success rate than those relying on the PA form alone.

The Clinical Evidence Behind Insulin Glargine

The decision to prescribe insulin glargine is well-supported by large outcomes data. TRICARE reviewers cannot question the clinical validity of basal insulin itself, only the brand choice.

The ORIGIN trial (Outcome Reduction with Initial Glargine Intervention), published in the New England Journal of Medicine in 2012, randomized 12,537 adults with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early T2D) to insulin glargine or standard care [8]. Over a median of 6.2 years, the glargine group achieved a median fasting glucose of 5.3 mmol/L vs. 6.2 mmol/L in the control group (P<0.001). The trial found no increase in cardiovascular mortality, no increase in cancer incidence, and a modest but statistically significant reduction in the progression to frank diabetes in the impaired-glucose subgroup [8]. This long-duration outcomes trial remains the most comprehensive cardiovascular safety dataset for any basal insulin and is frequently cited in medical necessity letters.

In pediatric T1D, a 28-week randomized trial (N=349) published in Diabetes Care demonstrated that insulin glargine produced lower rates of nocturnal hypoglycemia compared with NPH insulin while achieving equivalent HbA1c reduction [9]. The rate of confirmed nocturnal hypoglycemia was 1.05 events/patient-year with glargine vs. 1.86 events/patient-year with NPH (P<0.001) [9]. For pediatric T1D patients, this hypoglycemia-reduction data is directly relevant to a PA submission.

The ADA 2025 Standards of Care give insulin glargine a Level A recommendation for basal insulin use in both T1D and T2D [4]. Level A is the highest evidence grade in ADA's system, reserved for well-controlled randomized trials with clear clinical outcomes.

Biosimilar Alternatives: Clinical Equivalence and Device Differences

Semglee and Rezvoglar are FDA-designated interchangeable biosimilars to Lantus. "Interchangeable" is a specific FDA designation requiring the biosimilar to produce the same clinical result in any patient without additional provider intervention [5].

The FDA's interchangeability designation for Semglee, granted in July 2021, was based on pharmacokinetic and pharmacodynamic studies demonstrating equivalent glucose-lowering response and equivalent immunogenicity profile [5]. A 2022 analysis published in Diabetes, Obesity and Metabolism reviewed switching studies across multiple insulin biosimilars and found no clinically meaningful differences in HbA1c reduction or hypoglycemia rates when patients transitioned from originator to interchangeable biosimilar products [10].

Device differences, however, are real. Lantus is available in the SoloStar prefilled pen. Semglee uses the Semglee prefilled pen. The injection mechanism and dose dial differ between manufacturers. Patients who have used the SoloStar for years may need a brief training session before switching pens. This is a legitimate but minor clinical consideration, and it does not constitute a medical reason to avoid the biosimilar in most cases. For patients with significant dexterity limitations or visual impairment who are already trained on the SoloStar, device familiarity is a defensible PA argument [4].

What TRICARE Does Not Cover: Weight Loss Use of Lantus

Lantus is not indicated for weight loss and TRICARE will not approve it for that purpose. Insulin causes weight gain in most patients, not weight loss [4]. Any PA submission citing weight management as a reason for Lantus will be denied.

If you or your provider are considering a GLP-1 receptor agonist (semaglutide, tirzepatide) for obesity management alongside diabetes, those medications have separate coverage pathways. TRICARE covers Wegovy (semaglutide 2.4 mg) for obesity with documented BMI criteria and PA, and Zepbound (tirzepatide) under similar terms. That coverage is distinct from Lantus coverage and should be pursued through separate PA requests [11].

Cost and Savings Options

Lantus carries a manufacturer list price of approximately $340 per 30-day supply (five 3-mL SoloStar pens). Actual out-of-pocket cost under TRICARE's Tier 3 structure is lower but varies by beneficiary category [3].

The Sanofi Insulin Valyou savings card is not usable by TRICARE beneficiaries. Federal law (42 U.S.C. § 1320a-7b) prohibits using manufacturer copay assistance cards when a federal insurance program like TRICARE is the primary payer. Using such a card with TRICARE is considered an anti-kickback violation. Do not use manufacturer savings cards with TRICARE.

If cost remains a barrier after a denied appeal, the lowest-cost basal insulin option is Walmart's ReliOn brand insulin (NPH or regular), sold without prescription at approximately $25 per vial. This is not insulin glargine, and the pharmacokinetics differ significantly, so a provider should guide any transition. Basaglar, a non-interchangeable follow-on biologic for insulin glargine, is available through the TRICARE mail-order pharmacy as a preferred brand at a lower cost-share than Lantus and remains clinically equivalent for most patients [12].

TRICARE Plan Types and How Coverage Differs

TRICARE Prime, TRICARE Select, TRICARE for Life, and TRICARE Reserve Select each have different cost-share structures, but the formulary tier placement of Lantus is uniform across all plan types because it is governed by the DHA uniform formulary [3].

TRICARE for Life beneficiaries (Medicare-eligible military retirees) have Medicare as their primary payer. If Medicare Part D covers Lantus on its formulary at a lower cost-share than TRICARE's Tier 3 rate, Medicare Part D pays first. TRICARE for Life then covers the remaining cost-share, potentially reducing your net out-of-pocket to zero depending on your Part D plan tier structure. Review your Medicare Part D plan formulary separately, as each Part D plan sets its own tier placement for Lantus [13].

Active-duty service members receive care primarily through MTF pharmacies, where even Tier 3 drugs are typically dispensed at no cost when authorized. The PA and step therapy requirements still apply, but the financial impact is lower for active-duty compared with retirees or reservists filling at retail pharmacies.

Practical Steps for Beneficiaries

Getting Lantus covered under TRICARE requires a structured approach from day one.

Start by confirming the diagnosis coding on your prescription. An E10.9 (T1D without complications) or E11.65 (T2D with hyperglycemia) code on the PA request immediately signals medical necessity. A vague or missing ICD-10 code is the most common reason a PA fails on its first submission.

Ask your prescriber to include recent lab data. An HbA1c above 8% (64 mmol/mol) with documentation that current therapy is inadequate strengthens the necessity argument. A continuous glucose monitor (CGM) report showing time-below-range episodes on a previous regimen supports the case for stable Lantus continuation [4].

Request that your prescriber's office submit the PA at least two weeks before your current supply runs out. Express Scripts processes standard PAs within 14 days, and last-minute requests create gaps in coverage. If you are within five days of running out and the PA is still pending, ask your prescriber to request an urgent PA review, which carries a 72-hour response requirement [3].

If you are transitioning from a civilian insurance plan to TRICARE (for example, after a family member enters active-duty service), ask your previous insurer for a letter of prior authorization showing Lantus was covered. TRICARE may accept this as supporting evidence in a new PA request, reducing the documentation burden on your prescriber.

The Endocrine Society recommends against mandatory non-medical switching of stable insulin patients: "Transitions between insulin products should be made by physicians and patients together, based on clinical and patient-centered factors, not formulary pressure alone." [7] Include this quotation in appeal letters where TRICARE has denied continuation of an established Lantus regimen.